170th ENMC International Workshop: Bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 20, Issue 11, 2010, Pages 761-769

  Quinlivan, R ^a   Shaw, N ^b   Bushby, K ^c  

^a ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; DEFLAZACORT; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; VITAMIN D;

ARTICLE; BONE DENSITY; BONE PROTECTION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG INTERMITTENT THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; NETHERLANDS; PRIORITY JOURNAL; PROTECTION; VERTEBRA FRACTURE; WORKSHOP;

ADRENAL CORTEX HORMONES; BONE AND BONES; CONGRESSES AS TOPIC; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPOROSIS;

EID: 77957753154     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.07.272     Document Type: Article

References (62)

1. Quinlivan R., Roper H., Davie M., Shaw N.J., Mcdonagh J., Bushby K. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne Muscular Dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005, 15(1):72-79.
2. Biggar W.D., Bachrach L.K., Henderson R.C., Kalkwarf H., Plotkin H., Wong B.L. Bone health in Duchenne Muscular Dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005, 15(1):80-85.
3. Kinali M., Robinson R., Manzur A.Y., Burren C.P., Robb S.A. Backache in a Duchenne boy. Neuromuscul Disord 2007, 17(4):346-348.
4. Dovio A., Perazzolo L., Osella G., Ventura M., Termine A., Milano E., et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004, 89:4923-4928.
5. Vidal N.O., Brändström H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998, 159:191-195.
6. Vihinen M.K., Kolho K.L., Ashorn M., Verkasalo M., Raivio T. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008, 159:693-698.
7. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000, 39(12):1383-1389.
8. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13(10):777-787.
9. Clark E.M., Tobias J.H., Ness A.R. Association between bone mineral density and fractures in children: a systematic review and meta-analysis. Pediatrics 2006, 117(2):e291-e297.
10. van Staa T.P., Cooper C., Leufkens H.G., Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003, 18(5):913-918.
11. Boot A.M., Nauta J., Hokken-Koelega A.C., Pols H.A., de Ridder M.A., de Muinck Keizer-Schrama S.M. Renal transplantation and osteoporosis. Arch Dis Child 1995, 72(6):502-506.
12. Wetzsteon Rachel J., Shults Justine, Zemel Babette S., Gupta Pooja U., Burnham Jon M., Herskovitz Rita M., et al. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome. J Bone Miner Res 2009, 24:503-513.
13. Kanis J.A. An update on the diagnosis of osteoporosis. Curr Rheumatol Rep 2000, 2:62-66.
14. Kanis J., Mccloskey E., Johansson H., Strom O., Borgstrom F., Oden A. National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX=assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408.
15. Jones I.E., Taylor R.W., Williams S.M., Manning P.J., Goulding A. Four-year gain in bone mineral in girls with and without past forearm fractures: a DXA study. Dual energy X-ray absorptiometry. J Bone Miner Res 2002, 17(6):1065-1067.
16. Clark E.M., Ness A.R., Bishop N.J., Tobias J.H. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006, 21:1489-1495.
17. Hans D.B., Shepherd J.A., Schwartz E.N., Reid D.M., Blake G.M., Fordham J.N., et al. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11(1):188-206.
18. Mundy G.R. Cellular and molecular regulation of bone turnover. Bone 1999, 24(5 Suppl.):35S-38S.
19. Woitge H.W., Seibel M.J. Biochemical markers to survey bone turnover. Rheum Dis Clin North Am 2001, 27:49-80.
20. Delmas P.D., Garnero P. Utility of biochemical markers of bone turnover in osteoporosis. Osteoporosis 1996, 1075-1088. Academic Press, San Diego, CA, USA. R. Marcus, D. Feldman, J. Kelsey (Eds.).
21. Szulc P., Seeman E., Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000, 11:281-294.
22. Rauch F., Georg M., Stabrey A., Neu C., Blum W.F., Remer T., et al. Collagen markers deoxypyridinoline and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children. Clin Chem 2002, 48:315-322.
23. Cimaz R., Gattorno M., Sormani M.P., Falcini F., Zulian F., Lepore L., et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002, 29:1786-1792.
24. Bianchi M.L. How to manage osteoporosis in children. Best Pract Res Clin Rheumatol 2005, 19:991-1005.
25. Bianchi M.L., Mazzanti A., Galbiati E., Saraifoger S., Dubini A., Cornelio F., et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003, 14:761-767.
26. Söderpalm A.C., Magnusson P., Ahlander A.C., Karlsson J., Kroksmark A.K., Tulinius M., et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 2007, 17:919-928.
27. Soderpalm A.C., Magnusson P., Ahlander A.C., Karlsson J., Kroksmark A.K., Tulinius M., et al. Bone markers and bone mineral density in Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact 2008, 8(1):24.
28. Ferrar L., Jiang G., Schousboe J.T., Debold C.R., Eastell R. Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches. J Bone Miner Res 2008, 23:417-424.
29. Hansen K.E., Binkley N., Christian R., Vallarta-Ast N., Krueger D., Drezner M.K., et al. Inter-observer reproducibility of criteria for vertebral body exclusion. J Bone Miner Res 2005, 20:501-508.
30. Hsu J.D., Garcia-Ariz M. Fracture of the femur in the Duchenne muscular dystrophy patient. J Pediatr Orthop 1981, 1(2):203-207.
31. Vestergaard P., Henning G., Steffensen B., Rejnmark L., Rahbek J., Mosekilde L. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 2001, 33:150-155.
32. Larson C.M., Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000, 20:71-74.
33. Mcdonald D., Kinali M., Gallagher A.C., Mercuri E., Muntoni F., Roper H., et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 2002, 44:695-698.
34. Talim B., Malaguti C., Gnudi S., Politano L., Merlini L. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 2002, 12:294.
35. Dubowitz V. 47th ENMC Workshop. Neuromuscul Disord 1997, 7:261-267.
36. Bothwell J.E., Gordon K.E., Dooley J.M., Macsween J., Cummings E.A., Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr 2003, 42(4):353-356.
37. King W.M., Ruttencutter R., Nagaraja H.N., Matkovic V., Landoll J., Hoyle C., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68(19):1607-1613.
38. Houde S., Filiatrault M., Fournier A., Dube J., D'Arcy S., Berube D., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008, 38(3):200-206.
39. Manzur A.Y., Scott E., Munot P., Vijaykumar K., Muntoni F. National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health. Neuromuscul Disord 2010, 20(Suppl. 1):S8. on behalf of UK North Star Clinical Network (NSCN).
40. Kulshrestha R., Hoyle E., Davie M., Haddaway M., Quinlivan R. An audit of bone density and vertebral fractures during steroid treatment in Duchenne muscular dystrophy. Neuromuscl Disord 2010, 20(Suppl. 1):S8.
41. Biggar W.D., et al. A report of two deflazacort treatment protocols in Duchenne muscular dystrophy. Neuromuscul Disord 2003, 13:630.
42. Crabtree N.J., Roper H., Mcmurchie H., Shaw N.J. Regional changes in bone area and bone mineral content in boys with Duchenne muscular dystrophy receiving corticosteroid therapy. J Pediatr 2010, 156(3):450-455.
43. Bonjour J.P., Carrie A.L., Ferrari S., Clavien H., Slosman D., Theintz G., et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997, 99:1287-1294.
44. Chevalley T., Bonjour J.P., Ferrari S., Hans D., Rizzoli R. Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebo-controlled trial in prepubertal boys. J Clin Endocrinol Metab 2005, 90:3342-3349.
45. Matkovic V., Goel P.K., Badenhop-Stevens N.E., Landoll J.D., Li B., Ilich J.Z., et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005, 81:175-188.
46. Bonjour J.P., Chevalley T., Ammann P., Slosman D., Rizzoli R. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 2001, 358:1208-1212.
47. Huncharek M., Muscat J., Kupelnick B. Impact of dairy products and dietary calcium on bone-mineral content in children: results of a meta-analysis. Bone 2008, 43:312-321.
48. Winzenberg T., Shaw K., Fryer J., Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 2006, 333:775.
49. Rizzoli R, Bianchi ML, Garabédian M, Mckay HA, Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone 2009 Oct 17 [Epub ahead of print] PMID: 19840876.
50. Zamora S.A., Rizzoli R., Belli D.C., Slosman D.O., Bonjour J.P. Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. J Clin Endocrinol Metab 1999, 84:4541-4544.
51. Lehtonen-Veromaa M.K., Möttönen T.T., Nuotio I.O., Irjala K.M., Leino A.E., Viikari J.S. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study. Am J Clin Nutr 2002, 76:1446-1453.
52. Viljakainen H.T., Natri A.M., Kärkkäinen M., Huttunen M.M., Palssa A., Jakobsen J., et al. A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention. J Bone Miner Res 2006, 21:836-844.
53. Wagner C.L., Greer F.R. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122(5):1142-1152.
54. Hollick M.F. Medical progress: vitamin D deficiency. N Engl J Med 2007, 357:266-281.
55. Buck ML. Prevention and Management of Vitamin D Deficiency in Children: Part I: Vitamin D Requirements. Pediatric Pharmacotherapy, A Monthly e pub newsletter for health care professionals from the University of Virginia Children's Hospital; 2009.
56. Amin Shreyasee, Lavalley Michael P., Simms Robert W., Felson David T. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002, 17:1512-1526.
57. Shaw N.J., Boivin C.M., Crabtree N.J. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000, 83:143-145.
58. Acott P.D., Wong J.A., Lang B.A., Crocker J.F. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005, 20(3):368-373.
59. Hailwood Rudge S., Horne A., Lucas J., Wu F., Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005, 44:813-818.
60. Ward L, Tricco A, Phuong P, Cranney A, Barrowman N, Gaboury I et al. Bisphosphonate therapy for children with and adolescents with secondary osteoporosis. Cochrane database for systematic reviews; 2007, ncbi-n:CD005324.
61. Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009, 94:400-409.
62. Hawker G.A., Ridout R., Harris V.A., Chase C.C., Fielding L.J., Biggar W.D. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 2005, 86:284-288.